What is Immatics?
Immatics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of T cell-based immunotherapies for the treatment of cancer. The organization specializes in identifying novel, tumor-associated targets and engineering high-affinity T cell receptors to elicit a precise, robust immune response. By integrating deep scientific expertise with a sophisticated discovery platform, Immatics addresses significant unmet medical needs in oncology. Its business model relies on a dual approach: advancing an internal pipeline of innovative therapies while maintaining strategic alliances with global pharmaceutical leaders to accelerate the commercialization of its research. This hybrid strategy ensures that the company remains agile in its R&D efforts while benefiting from the operational scale and distribution capabilities of established industry partners.
How much funding has Immatics raised?
Immatics has raised a total of $392.5M across 8 funding rounds:
Series A
$9.9M
Series B
$52.1M
Series C
$71.2M
Series D
$16.3M
Other Financing Round
$30M
Other Financing Round
$58M
Share Placement
$35M
Private Equity
$120M
Series A (2004): $9.9M with participation from EMBL Ventures, Merifin Capital, 3i Group, and VINCI CAPITAL
Series B (2007): $52.1M led by NTEC, OH Beteiligungen, DH Capital, KfW, and 3i Group
Series C (2010): $71.2M supported by MIG Capital, dievini Hopp Biotech Holding, and AT Impf
Series D (2013): $16.3M featuring Wellington Partners, dievini Hopp BioTech, and MIG Funds
Other Financing Round (2017): $30M backed by Amgen
Other Financing Round (2017): $58M with participation from Amgen, AT Impf, and dievini Hopp Biotech Holding
Share Placement (2023): $35M led by Bristol-Myers Squibb
Private Equity (2023): $120M supported by Moderna
Key Investors in Immatics
Moderna
Moderna is a pioneer in mRNA medicine, reshaping the way treatments and vaccines are created and delivered across infectious conditions, cancer, and rare disorders.
Bristol-Myers Squibb
A global biopharmaceutical organization focused on discovering and developing innovative medications for serious diseases, including oncology and immunoscience.
Amgen
A leading multinational biotechnology company that pioneered the industry and remains at the forefront of scientific innovation in therapeutic development.
What's next for Immatics?
With the recent infusion of capital, Immatics is well-positioned to accelerate its clinical development programs and expand its manufacturing capabilities for Adoptive Cell Therapies. The strategic focus will likely shift toward optimizing the delivery of its TCR-based pipeline and deepening its collaborative research efforts with major industry players. As the company moves further into late-stage clinical trials, the emphasis will remain on demonstrating the efficacy and safety of its therapeutic candidates, ultimately aiming to secure regulatory approvals that could redefine standard-of-care protocols in oncology. The ongoing support from high-profile investors suggests a long-term commitment to scaling the company's platform and achieving sustainable market impact in the competitive landscape of precision medicine.
See full Immatics company page
